CPEB2

Across TCGA pan-cancer cohorts, CPEB2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CPEB2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CPEB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPEB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where CPEB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.344	0.869	.006	9	view →
UCEC	OS	Median	All	1.000	0.704	.004	8	view →
CCRCC	DFS	Tertile	II,III,IV	0.418	0.783	.015	6	view →
HNSC	DFS	Median	IV	0.635	0.891	.028	3	view →
LSCC	DFS	Median	II,III,IV	0.820	1.000	.029	3	view →
LUAD	DFS	Median	All	0.428	0.697	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CPEB2–PDAC (DFS)

Open the PDAC breakdown →